Tempest Therapeutics (TPST) Non Operating Income (2018 - 2026)
Tempest Therapeutics (TPST) posted Non Operating Income of $56000.0 for Q4 2025, down 34.88% sequentially from $86000.0 in Q3 2025, and down 46.67% YoY from $105000.0 in Q4 2024.
Tempest Therapeutics (TPST) Non Operating Income (2018 - 2026) Analysis & Trends
Tempest Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $56000.0 in Q4 2025.
- Quarterly Non Operating Income fell 46.67% year-over-year to $56000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $314000.0 (up 72.53% YoY) and the FY2025 annual result came in at $313000.0, up 71.04% from the prior year.
- Non Operating Income retreated to $56000.0 in Q4 2025 per TPST's latest filing, from $86000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $105000.0 in Q4 2024 and troughed at -$441000.0 in Q4 2021.
- A 5-year average of -$111150.0 and a median of -$83000.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2021 and 2025: Non Operating Income slumped 5560.0% in 2021, then surged 1820.0% in 2025.
- Over 5 years, Non Operating Income stood at -$441000.0 in 2021, then jumped by 61.68% to -$169000.0 in 2022, then soared by 115.38% to $26000.0 in 2023, then soared by 303.85% to $105000.0 in 2024, then tumbled by 46.67% to $56000.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $56000.0, $86000.0, and $96000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Dec 31, 2025 | 56,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | -194,000.00 |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -55,000.00 |
| Dec 31, 2022 | -169,000.00 |
| Sep 30, 2022 | -176,000.00 |
| Jun 30, 2022 | -394,000.00 |
| Mar 31, 2022 | -330,000.00 |
| Dec 31, 2021 | -441,000.00 |
| Sep 30, 2021 | -374,000.00 |
| Jun 30, 2021 | -273,000.00 |